801 related articles for article (PubMed ID: 32830166)
1. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
2. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
3. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocellular Carcinoma.
Vogel A; Saborowski A
Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
[TBL] [Abstract][Full Text] [Related]
6. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
[TBL] [Abstract][Full Text] [Related]
7. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
8. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
9. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
10. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016.
Wang J; Bo X; Nan L; Wang CC; Gao Z; Suo T; Ni X; Liu H; Lu P; Wang Y; Liu H
Cancer Med; 2020 Feb; 9(4):1335-1348. PubMed ID: 31876990
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial.
Goetze TO; Bechstein WO; Bankstahl US; Keck T; Königsrainer A; Lang SA; Pauligk C; Piso P; Vogel A; Al-Batran SE
BMC Cancer; 2020 Feb; 20(1):122. PubMed ID: 32059704
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma: State of the Art.
Moazzami B; Majidzadeh-A K; Dooghaie-Moghadam A; Eslami P; Razavi-Khorasani N; Iravani S; Khoshdel A; Shahi F; Dashti H; Mehrvar A; Nassiri Toosi M
J Gastrointest Cancer; 2020 Sep; 51(3):774-781. PubMed ID: 32157571
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
15. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
17. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.
Glazer ES; Liu P; Abdalla EK; Vauthey JN; Curley SA
J Gastrointest Surg; 2012 Sep; 16(9):1666-71. PubMed ID: 22777053
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
[TBL] [Abstract][Full Text] [Related]
19. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
20. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
